LIGHT deficiency aggravates cisplatin-induced acute kidney injury by upregulating mitochondrial apoptosis

被引:10
作者
Yang, Yan [1 ,2 ,3 ]
Menga, Li [1 ]
Wu, Shun [4 ]
Li, You [3 ]
Zhong, Yu [1 ]
Xu, Feng [2 ]
Zhou, Xiao-cui [5 ]
Li, Gui-qing [2 ]
Xu, Gui-lian [2 ]
Peng, Kan-fu [1 ]
机构
[1] Third Mil Med Univ, Army Med Univ, Affiliated Hosp 1, Dept Nephrol, Chongqing 400038, Peoples R China
[2] Third Mil Med Univ, Army Med Univ, Dept Immunol, Chongqing 400038, Peoples R China
[3] Third Mil Med Univ, Army Med Univ, Daping Hosp, Dept Intens Care Med,Affiliated Hosp 3, Chongqing 400042, Peoples R China
[4] Xuzhou Med Univ, Huaihai Hosp, Dept Nephrol, Xuzhou 221004, Jiangsu, Peoples R China
[5] Chongqing Med & Pharmaceut Coll, Affiliated Hosp 1, Dept Intens Care Med, Chongqing 400006, Peoples R China
基金
中国国家自然科学基金;
关键词
LIGHT; Cisplatin; Acute kidney injury; Mitochondrial apoptosis; HERPESVIRUS ENTRY MEDIATOR; SUPERFAMILY; RECEPTOR; ACTIVATION; PATHWAYS; MEMBER; FAMILY; CELLS; BTLA;
D O I
10.1016/j.intimp.2020.106999
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cisplatin is widely used as a chemotherapeutic agent for treating patients with solid tumors. The most common side effect of cisplatin treatment is nephrotoxicity. Recent studies have shown that mitochondrial apoptotic pathways are involved in cisplatin-induced acute kidney injury (Cis-AKI). LIGHT, the 14th member of the tumor necrosis factor superfamily (TNFSF14), was found to induce apoptosis of certain types of tumor cells. So far, a link between LIGHT and Cis-AKI has not been reported. In this study, we observed that expression of LIGHT and its receptors HVEM and LT beta R was increased in kidney tissues of mice after cisplatin treatment. LIGHT deficiency aggravated kidney injury, as evidenced by more severe tubular injury; remarkably increased levels of serum creatinine (Scr), blood urea nitrogen (BUN), and both kidney injury molecule-1 (KIM-1) and inflammatory cytokine mRNAs in renal tissues. Moreover, in the renal tissues of LIGHT KO mice, cisplatin-induced mitochondrion injury and the levels of the pro-apoptotic molecules Bax, Cytochrome C (Cyt C), cleaved caspase-3, and cleaved caspase-9 were dramatically increased; in contrast, the expression of anti-apoptotic molecule Bcl-2 was markedly reduced, compared to those in WT mice, suggesting that LIGHT deficiency accelerated cisplatin-induced mitochondrial apoptosis of renal tubular cells in these mice. Accordingly, treatment with recombinant human LIGHT (rLIGHT) was shown to alleviate cisplatin-induced kidney injury in vivo. Similar results were observed after the human renal tubular epithelial cell line HK-2 cells exposure to rLIGHT stimulation, evidenced by the reduction in the mitochondrion dysfunction (as confirmed by the significant reduced oxidative stress and membrane potential changes) and in the percentage of cells apoptosis. While blocking LIGHT with the soluble fusion protein LT beta R-Ig or HVEM-Ig accelerated the HK-2 cells apoptosis. In conclusion, LIGHT deficiency aggravates Cis-AKI by promoting mitochondrial apoptosis pathways.y
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Roxadustat protects rats from cisplatin-induced acute kidney injury
    Arikan, Cuneyt
    Bora, Ejder Saylav
    Arda, Duygu Burcu
    Erbas, Oytun
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2024, 23 (07) : 1077 - 1082
  • [42] MicroRNA-214-3p aggravates ferroptosis by targeting GPX4 in cisplatin-induced acute kidney injury
    Zhou, Junran
    Xiao, Chengcheng
    Zheng, Shuaishuai
    Wang, Qian
    Zhu, Hai
    Zhang, Yingyu
    Wang, Renhe
    CELL STRESS & CHAPERONES, 2022, 27 (04) : 325 - 336
  • [43] 14-3-3ζ targets β-catenin nuclear translocation to maintain mitochondrial homeostasis and promote the balance between proliferation and apoptosis in cisplatin-induced acute kidney injury
    Sun, Zhaoxing
    Ning, Yichun
    Wu, Huan
    Guo, Shulan
    Jiao, Xiaoyan
    Ji, Ji
    Ding, Xiaoqiang
    Yu, Xiaofang
    CELLULAR SIGNALLING, 2023, 111
  • [44] Luteolin ameliorates cisplatin-induced acute kidney injury in mice by regulation of p53-dependent renal tubular apoptosis
    Kang, Kyung Pyo
    Park, Sung Kwang
    Kim, Duk Hoon
    Sung, Mi Jeong
    Jung, Yu Jin
    Lee, Ae Sin
    Lee, Jung Eun
    Ramkumar, Kunka Mohanram
    Lee, Sik
    Park, Moon Hyang
    Roh, Si-Gyun
    Kim, Won
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2011, 26 (03) : 814 - 822
  • [45] Renalase attenuates mitochondrial fission in cisplatin-induced acute kidney injury via modulating sirtuin-3
    Huang, Zhimin
    Li, Qing
    Yuan, Yanggang
    Zhang, Chengning
    Wu, Lin
    Liu, Xi
    Cao, Wei
    Guo, Honglei
    Duan, Suyan
    Xu, Xueqiang
    Zhang, Bo
    Xing, Changying
    LIFE SCIENCES, 2019, 222 : 78 - 87
  • [46] MicroRNA-214-3p aggravates ferroptosis by targeting GPX4 in cisplatin-induced acute kidney injury
    Junran Zhou
    Chengcheng Xiao
    Shuaishuai Zheng
    Qian Wang
    Hai Zhu
    Yingyu Zhang
    Renhe Wang
    Cell Stress and Chaperones, 2022, 27 : 325 - 336
  • [47] Interleukin-6 deficiency accelerates cisplatin-induced acute renal failure but not systemic injury
    Mitazaki, S.
    Kato, N.
    Suto, M.
    Hiraiwa, K.
    Abe, S.
    TOXICOLOGY, 2009, 265 (03) : 115 - 121
  • [48] Original The effect of monotropein on alleviating cisplatin-induced acute kidney injury by inhibiting oxidative damage, inflammation and apoptosis
    Zhang, Yuping
    Chen, Yonger
    Li, Baixue
    Ding, Ping
    Jin, Daxiang
    Hou, Shaozhen
    Cai, Xiaochun
    Sheng, Xiujie
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 129
  • [49] The novel STING antagonist H151 ameliorates cisplatin-induced acute kidney injury and mitochondrial dysfunction
    Gong, Wei
    Lu, Lingling
    Zhou, Yu
    Liu, Jiaye
    Ma, Haoyang
    Fu, Lvhan
    Huang, Songming
    Zhang, Yue
    Zhang, Aihua
    Jia, Zhanjun
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2021, 320 (04) : F608 - F616
  • [50] Activation of Sirtuin 3 by Silybin Attenuates Mitochondrial Dysfunction in Cisplatin-induced Acute Kidney Injury
    Li, Yin
    Ye, Zengchun
    Lai, Weiyan
    Rao, Jialing
    Huang, Wanbing
    Zhang, Xiaohao
    Yao, Ziying
    Lou, Tanqi
    FRONTIERS IN PHARMACOLOGY, 2017, 8